Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial-Reference-Cited by-同舟云学术

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Published:2021-02 Issue:10274 Volume:397 Page:592-604
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Sezer Ahmet,Kilickap Saadettin,Gümüş Mahmut,Bondarenko Igor,Özgüroğlu Mustafa,Gogishvili Miranda,Turk Haci M,Cicin Irfan,Bentsion Dmitry,Gladkov Oleg,Clingan Philip,Sriuranpong Virote,Rizvi Naiyer,Gao Bo,Li Siyu,Lee Sue,McGuire Kristina,Chen Chieh-I,Makharadze Tamta,Paydas Semra,Nechaeva Marina,Seebach Frank,Weinreich David M,Yancopoulos George D,Gullo Giuseppe,Lowy Israel,Rietschel Petra

Funder

Sanofi

Regeneron Pharmaceuticals

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Frontline immunotherapy for NSCLC: alone or not alone?;Gridelli;Nat Rev Clin Oncol,2018

2. Immunotherapy in treatment naïve advanced non-small cell lung cancer;Ernani;J Thorac Dis,2018

3. Pembrolizumab versus chemotherapy for PD-L1–positive non-small-cell lung cancer;Reck;N Engl J Med,2016

4. Pembrolizumab versus docetaxel for previously treated, PD–L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

5. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N Engl J Med,2015

Cited by 526 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Globalization of clinical research in oncology: Status, challenges, and future directions;Journal of Cancer Policy;2024-12

2. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review;International Immunopharmacology;2024-11

3. Dual-signal output biosensor for the detection of program death-ligand 1 and therapy progress monitoring of cancer;Biosensors and Bioelectronics;2024-10

4. β-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer;BMC Immunology;2024-09-14

5. Brain Metastases as Inaugural Sign of Non-Small Cell Lung Carcinoma: Case Series and Review of Literature;Cancers;2024-09-08